Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2020-09-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于签订创新药产业化（嵊州）基地项目投资协议书的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the signing of an investment agreement for an innovative drug industrialization base project. It details the agreement's terms, parties involved, investment amount, project overview, risk warnings, and board approval. The document is an announcement of a capital investment agreement and does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it relates to a significant investment project agreement and capital expenditure plans.
2020-09-29 Chinese
第三届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 11th meeting of the 3rd Board of Directors of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and the approval of an investment agreement for a new industrial base. There is no financial data, earnings information, or detailed report content. The document focuses on board decisions and meeting procedures, which aligns with announcements about board or management information. It is not an annual report, audit report, or earnings release. The document is not a proxy solicitation or voting result announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and content support a high confidence in this classification.
2020-09-29 Chinese
关于诉讼案件进展的公告
Legal Proceedings Report Classification · 100% confidence The document is a public announcement from a company regarding the progress of a litigation case. It details the basic facts of the lawsuit, recent developments including a ruling by the Supreme People's Court, and the potential impact on the company's profits. It references previous announcements and states that no other significant litigation exists. The document is short (1173 characters) and focuses on legal proceedings rather than financial results or management changes. It does not contain financial statements or detailed financial analysis. Therefore, it fits the category of a Legal Proceedings Report (LTR).
2020-09-29 Chinese
关于股东减持计划实施完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a shareholder's stock reduction plan. It details the number of shares reduced, the periods, prices, and the shareholder's holdings before and after the reduction. It references compliance with relevant regulations on shareholder stock reduction. There is no financial statement, earnings data, or management discussion. The document is a formal disclosure of a shareholder's transaction in their own shares, specifically a reduction in holdings. This fits the category of 'Transaction in Own Shares' (POS). The document length is 2669 characters, which is consistent with an announcement rather than a full report.
2020-09-25 Chinese
独立董事关于第三届董事会第十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's third board of directors' tenth meeting. It includes opinions on authorization for a specific stock issuance and the appointment of the board secretary. The content focuses on board/management decisions and approvals rather than financial results, audit opinions, or regulatory announcements. The document is relatively short (1427 characters) and does not contain financial statements or detailed financial data. It is not a report publication announcement or a certification. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions in the company's board or senior management.
2020-09-24 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Betta Pharmaceuticals Co. Ltd. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and other governance matters. It references relevant laws such as the Company Law of the People's Republic of China and Securities Law. The content is a comprehensive governance document that sets out the internal rules and regulations of the company rather than financial results, audit opinions, or meeting announcements. It is not a report of financial performance, nor an announcement or transcript of a meeting, nor a regulatory filing or dividend notice. Therefore, the document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2020-09-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.